Storys aus ZUG, Switzerland

Shire Pharmaceuticals Group Plc

Shire Granted EU Conditional Marketing Authorisation for Natpar[®] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Zug, Switzerland (ots/PRNewswire) - Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), the ...

Shire Pharmaceuticals Group Plc

Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI)

Zug, Switzerland (ots/PRNewswire) - Shire launches campaign to raise global awareness during World PI Week Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, is launching #PIPostsThanks, a social campaign to spotlight the unsung heroes who make a difference in the lives of people living with primary immunodeficiency (PI). PI is a group of nearly ...

Shire Pharmaceuticals Group Plc

Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide

Zug, Switzerland (ots/PRNewswire) - On World Hemophilia Day 2017, Shire challenges the community to collectively improve global standards of care for rare bleeding disorders Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotechnology company focused on serving individuals with rare diseases, joins the global ...

Shire Pharmaceuticals Group Plc

INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan

Zug, Switzerland (ots/PRNewswire) - A New Non-stimulant Clinical Option for Children and Adolescents From 6 to 17 Years old With ADHD Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that its partner in Japan, Shionogi & Co., Ltd, has received the approval of the Japanese Ministry of Health, Labor and Welfare to ...

Shire Pharmaceuticals Group Plc

Shire Receives European Approval for Label Extension of CINRYZE®(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE

Zug, Switzerland (ots/PRNewswire) - CINRYZE is now the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the European Commission (EC) has approved a label extension granting three new indications for CINRYZE® (C1 inhibitor ...

Shire Pharmaceuticals Group Plc

CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism

Zug, Switzerland (ots/PRNewswire) - This Press Release is intended for Global Use If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment[1] Shire plc (LSE: SHP, ...

Shire Pharmaceuticals Group Plc

New Data From Shire Aim To Help Close the Diagnosis and Treatment Gap for People With Hemophilia

Zug, Switzerland (ots/PRNewswire) - Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, presented its new estimate of the Global Annual Bleed Rate (GABR), an effort to build on current global ...

Pala Investments

Pala Investments Completes Sale of Its Interest in Sierra Rutile Limited

Zug, Switzerland (ots/PRNewswire) - Pala Investments ("Pala"), an investment company focused on the mining and metals value chain, announces today the successful completion of the sale of its 53 percent interest in Sierra Rutile Limited ("Sierra Rutile"), the world's largest producer of natural rutile, to Iluka Resources. The transaction valued Sierra Rutile at £215 ...

Shire Pharmaceuticals Group Plc

ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy

Zug, Switzerland (ots/PRNewswire) - The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Shire plc (LSE: SHP, NASDAQ: SHPG) today ...

Shire Pharmaceuticals Group Plc

Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe

Zug, Switzerland (ots/PRNewswire) - HyQvia (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) is the only subcutaneous IG treatment for primary and certain secondary immunodeficiencies that can be administered in one site, once a month (up to every four weeks) Shire plc (LSE: SHP, NASDAQ: SHPG) is launching a pediatric indication for HyQvia (Human ...

Shire Pharmaceuticals Group Plc

Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)

Zug, Switzerland (ots/PRNewswire) - This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of ...

Shire Pharmaceuticals Group Plc

Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru

Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...

Shire Pharmaceuticals Group Plc

Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome

Zug, Switzerland (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the extension of the approval of Revestive[®*] (teduglutide) 5 mg powder and solvent for ...

Shire Pharmaceuticals Group Plc

Shire Announces Winners of Spotlight on Gaucher Film Contest to Mark International Gaucher Day

Zug, Switzerland (ots/PRNewswire) - Shire plc is pleased to announce the winner and runner up of the Spotlight on Gaucher film contest on the occasion of International Gaucher Day (IGD). The film contest, which was supported by the European Gaucher Alliance (EGA), encouraged people whose lives have been touched by Gaucher disease to share a video to raise awareness of ...

Shire Pharmaceuticals Group Plc

Shire Receives European Approval for INTUNIV®? (Guanfacine Hydrochloride Prolonged Release Tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents

Zug, Switzerland (ots/PRNewswire) - The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU    Shire today announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV(R) (guanfacine hydrochloride prolonged release ...

Shire Pharmaceuticals Group Plc

Shire Receives European Approval to Use Resolor® (prucalopride) in Men for the Symptomatic Treatment of Chronic Constipation

Zug, Switzerland (ots/PRNewswire) - For Release in Europe Only - Resolor was approved in 2009 in Europe for use in women for the symptomatic treatment of chronic constipation in whom laxatives fail to provide adequate relief[1] Shire plc announced today that Resolor (prucalopride) has been approved by the European ...

Shire Pharmaceuticals Group Plc

Shire Added to Global 100 Sustainability Index

Lexington, Massachusetts And Zug, Switzerland (ots/PRNewswire) - Shire plc announces that it has for the first time placed in the Global 100 Sustainability Index. Shire was ranked 62nd in the index, which is being revealed during the World Economic Forum in Davos this week. The Global 100 Index is a global ranking by Canada-based media and investment advisory company, Corporate Knights, of the top sustainability ...

Wire

Wire Launches Modern Communications Network

Zug, Switzerland (ots/PRNewswire) - Simple, beautiful conversations on your phone, tablet and desktop A team of more than 50 people from 23 countries, supported by Skype co-founder Janus Friis, is launching Wire, a communications network for messaging, voice calling, sharing pictures, music and video on your phone, tablet and desktop. (Logo: http://photos.prnewswire.com/prnh/20141203/719919 ) "Skype was launched more than ...

Hitachi Medical Systems Europe Holding AG

2

Hitachi Aloka Medical presents the New Brand ARIETTA(*1) with two New Ultrasound Products ARIETTA 70 and ARIETTA 60 (PICTURE)

Infront Sports & Media AG

Infront fosters further organic growth with the opening of a new Pan-Asia subsidiary in Singapore

Singapore/Zug,Switzerland (ots) - The group takes its comprehensive sales, marketing and client services to the region, whilst also offering a gateway to its broad sports portfolio Infront Sports & Media, the leading international sports marketing company, has opened a new office in Singapore. The wholly-owned subsidiary under the name Infront Pan-Asia became fully ...

Hitachi Medical Systems Europe Holding AG

Hitachi Aloka Medical Releases Noblus, Advanced Versatile Ultrasound with Flexible Style (PICTURE)

Cardiorentis

Cardiorentis initiates first-ever acute heart failure Phase III clinical trial designed to assess early treatment on cardiovascular mortality and symptoms

Zug, Switzerland (ots/PRNewswire) - Cardiorentis has initiated the first-ever acute heart failure (AHF) Phase III trial to be specifically designed to assess the effect of early treatment on cardiovascular mortality. TRUE-AHF (TRial of Ularitide's Efficacy and safety in patients with Acute Heart Failure) aims to ...

Actavis Inc.

Watson Pharmaceuticals, Inc. is Now Actavis, Inc. (PICTURE)

Quantum Global Corporate Servives AG

Quantum Global and Lasalle Investment Management target New York with second acquisition / Joint Venture Plaza acquires 49.5% stake in Fifth Avenue office block

Zug, Switzerland / London, GB (ots) - Quantum Global Real Estate ("Quantum Global") und LaSalle Investment Management ("LaSalle") announce that Plaza Global Real Estate Partners ("Plaza"), their joint venture, has contracted to purchase a 49.5% interest in 521 Fifth Avenue from SL Green Realty Corp. (NYSE: SLG) ("SL ...

Hitachi Medical Systems Europe Holding AG

ECR 2012: Hitachi Medical Systems Europe Holding AG to present its new, combined Hitachi Aloka ultrasound portfolio and a new era in MR imaging

Zug, Switzerland (ots) - - - First ECR presentation of the combined Hitachi and Aloka ultrasound portfolio with its many highlights - New upgrades for ProSound F75 - New ergonomic lightweight ultrasound system F37 - Image fusion with Hitachi Real-time Virtual Sonography - A new era in MR imaging: the Echelon Oval ...